Teva Seeks to Block Lilly’s Competing, Unapproved Migraine Drug

• Teva seeking FDA approval for biologic to treat episodic and chronic migraine

• Struggling company says Eli Lilly’s competitor product, also under FDA review, infringes two patents

Teva Pharmaceuticals International GmbH says an Eli Lilly and Co. yet-to-be-approved migraine drug infringes patents on its own putative migraine product as the Israeli drugmaker seeks to pull out of a tailspin.

Eli Lilly’s galcanezumab biologic infringes Teva’s U.S. Patent Nos.9,884,907and9,884,908, which cover the fremanezumab biologic, Teva said in alawsuitfiled Feb. 6. Both drugs await Food and Drug Administration approval.

Teva said in its suit it has “invested ...